Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Global Anti-nuclear Antibody (ANA) Testing Market Overview
The Anti-nuclear Antibody (ANA) testing market size is expected to reach USD 1.6 billion by 2032 at 11.3% CAGR during the forecast period 2023-2032. Antinuclear Antibody (ANA) Test detects antinuclear antibodies in the blood. The immune system makes antibodies to fight infections. Antinuclear antibodies attack on own tissues. It helps to recognize autoimmune diseases such as rheumatoid arthritis and lupus. The rise in technological advancements, higher adoption rate of new techniques, and growing concern of autoimmune diseases are driving the antinuclear antibody (ANA) testing market growth. Major industrial players are investing in research and development for the development of advanced products, which is another key growth factor for the market.
North America holds the prime position in Anti-nuclear Antibody (ANA) Testing market. U.S. hold the largest share and the European region is the second-largest and due to the higher growth rate in west European countries. The Asia-Pacific (APAC) is rapidly growing and significantly maintains a significant growth rate in the forecast period. The Middle East and Africa (ME&A) will show limited growth due to less awareness of devices and treatment. This regional development will boost the global growth rate of the market.
September 2023
Metropolis declares the introduction of a novel antibody assay for severe renal disease.
Nephrotic Syndrome, one of the most serious renal conditions, is characterized by persistent edema and significant loss of urinary proteins.
Membranous Nephropathy, also known as Membranous Glomerulonephritis, is a prominent etiology of Nephrotic Syndrome. It is a chronic inflammatory disorder affecting the glomeruli, the initial capillary network in the kidneys responsible for blood filtration. Membranous nephropathy is characterized by the formation of an immune complex, which is an antibody-antigen complex, within the glomerulus. Ultimately, this results in renal dysfunction and the development of kidney failure.
Primary glomerulonephropathy (idiopathic) occurs when the etiology of the disease is unknown. Secondary glomerulonephropathy may be caused by an underlying condition such as chronic infection, tumor, cancer, or specific medications, among others.
Differentiating primary from secondary is crucial due to the variations in treatment approaches and disease management strategies. Primary Membranous Nephropathy is treated with an immunosuppressive therapy or kidney transplantation; secondary nephropathy involves treatment of the underlying disease.
The PLA2R Antibody Test is utilized to accurately distinguish between the two types of diseases, assess the disease's severity, monitor treatment, and determine the patient's risk following a kidney transplant.
Activity of the disease (proteinuria) is correlated with anti-PLA2R autoantibody results. There exists a direct correlation between elevated titers and the severity of primary MN.
A reduction in the anti-PLA2R autoantibody titer is observed in patients who respond favorably to immunosuppressive therapy. Recurrence of the antibodies is correlated with a relapse of the disease. In addition, a high anti-PLA2R titer was identified as a significant risk factor for patients with primary MN who do not experience proteinuria remission.
After undergoing kidney transplantation, up to 40% of patients with primary MN relapse. A persistent presence of anti-PLA2R autoantibodies for a duration of six months following organ transplantation significantly elevates the associated risk. Consequently, in order to prevent relapses, the titer may be utilized to determine the need for and efficacy of immunosuppressive therapy following a transplant.
Anti-nuclear Antibody Antibody (ANA) Testing Market Segment Insights
Anti-nuclear Antibody Antibody (ANA) Testing Type Insights
Anti-nuclear Antibody (ANA) Testing Market has been segmented on the basis of type which comprise immunofluorescence (Primary or direct and Secondary or indirect), enzymelinked, immunosorbent assay (ELISA) (Direct ELISA, Indirect ELISA, Sandwich ELISA, Competition/Inhibition ELISA), and others.
Anti-nuclear Antibody (ANA) Testing Application Insights
On the basis of application, it segmented into Rheumatoid arthritis (Seropositive, Seronegative), Systemic lupus erythematosus (SLE) (Discoid lupus erythematosus, Subacute cutaneous lupus erythematosus, Neonatal lupus), Polymyositis, Scleroderma (localized scleroderma, systemic scleroderma), Sjögren's syndrome (Primary, secondary) , and others.
Anti-nuclear Antibody (ANA) Testing End-user Insights
On the basis of end user, it segmented into Hospitals and clinics, research laboratories, and others.
Anti-nuclear Antibody (ANA) Testing Regional Insights
Considering the global scenario of the market, North America is largest market for Anti-nuclear Antibody (ANA) Testing, in North America region US hold largest market share while European market is second largest, and especially the growth rate is higher in west European countries. On the other hand, Asia-Pacific (APAC) is fastest growing market and expected to grow significantly during the forecast period. Middle East and Africa (ME&A) is likely to have a limited growth in the market due to less awareness of devices and treatment.
Key companies in the Anti-nuclear Antibody (ANA) Testing Market include:
- Abcam plc. (US)
- Alere (US)
- Antibodies Inc.(US)
- Bio-Rad Laboratories, Inc. (US)
- Erba Diagnostics (US)
- Indur Services, Inc. (US)
- MBL INTERNATIONAL (US)
- Merck KGaA (Germany)
- Trinity Biotech (Republic of Ireland)
Study objectives of Anti-nuclear Antibody (ANA) Testing Market:
- To provide detailed analysis of the Anti-nuclear Antibody (ANA) Testing market structure with historical and forecast revenue for the next 7 years of the various segments and sub-segments of the Anti-nuclear Antibody (ANA) Testing Market
- To provide insights about the key drivers, restraints, opportunities and challenges that affecting the growth of the Anti-nuclear Antibody (ANA) Testing market
- To provide analysis of the market with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.
- To provide detail analysis of the market that segmented on the basis of type, by application, by end user, and its sub-segments.
- To provide detail analysis of Anti-nuclear Antibody (ANA) testing market mainly based on value chain analysis, Porter’s five forces, Price analysis, and Supply Chain analysis etc.
- To provide detail country level analysis of the market with respect to the current market size and future prospective
- To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Anti-nuclear Antibody (ANA) Testing Market
- To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the Anti-nuclear Antibody (ANA) Testing market
Recent Development
In May 2022
The U.S. Food and Drug Administration (FDA) has cleared ZEUS Scientific's dIFine® digital immunofluorescence system* for use with ZEUS' ANA HEp-2 indirect fluorescent antibody (IFA) assay.
The FDA-cleared ZEUS dIFine® digital immunofluorescence system is the next generation in IFA imaging and pattern recognition designed to acquire, analyze, display and store digital images of ZEUS IFA HEp-2 cells. An automated digital scanner with intelligent software, ZEUS dIFine quickly delivers positive/negative results and has been programmed to suggest eight common ANA HEp-2 patterns (homogenous, speckled, centromere, nucleolar, nuclear dots, nuclear membrane, cytoplasmic (ribosomal and mitochondrial)). dIFine also instantly locates and identifies mitotic cells to assist in pattern identification. Quickly viewing and validating all negative samples with a single mouse click saves the user valuable time.
Anti-nuclear Antibody (ANA) Testing Market, by Region
- Americas
- North America
- US
- Canada
- Latin America
- Europe
- Western Europe
- Germany
- France
- Italy
- Spain
- UK
- Rest of Western Europe
- Eastern Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- The Middle East & Africa
- Middle East
- Africa
Research Methodology:
The report for Anti-nuclear Antibody (ANA) Testing Market of Market Research Future comprises extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.
Intended Audience
- Anti-nuclear Antibody (ANA) Test products manufacturers
- Anti-nuclear Antibody (ANA) Test products and services providers
- Medical Research laboratories
- Research and Development (R&D) Companies
- Market Research and Consulting Service Providers
- Potential Investors
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
